Methods of modulating drug plasma levels using erythrohydroxybupropion
View Patent ↗This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed
1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in an AUC 0-12 of dextromethorphan that is at least about 40 ng·hr/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC 0-12 of dextromethorphan is at least about 20 times the AUC 0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
2. The method of claim 1 , wherein the AUC 0-12 of dextromethorphan is at least about 50 ng·hr/mL.
3. The method of claim 1 , wherein the AUC 0-12 of dextromethorphan on the eighth day is at least about 100 ng·hr/mL.
4. The method of claim 1 , wherein the AUC 0-12 of dextromethorphan on the eighth day is at least about 400 ng·hr/mL.
5. The method of claim 1 , wherein the AUC 0-12 of dextromethorphan on the eighth day is at least about 700 ng·hr/mL.
6. The method of claim 1 , wherein the AUC 0-24 of dextromethorphan on the eighth day is at least about 100 ng·hr/mL.
7. The method of claim 1 , wherein the AUC 0-24 of dextromethorphan on the eighth day is at least about 1000 ng·hr/mL.
8. The method of claim 1 , wherein the AUC 0-inf of dextromethorphan on the eighth day is at least about 100 ng·hr/mL.
9. The method of claim 1 , wherein the AUC 0-inf of dextromethorphan on the eighth day is at least about 2000 ng·hr/mL.
10. The method of claim 1 , wherein the AUC 0-inf of dextromethorphan on the eighth day is at least about 3000 ng·hr/mL.
11. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in a C max of dextromethorphan that is at least about 6 ng/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC 0-12 of dextromethorphan is at least about 20 times the AUC 0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
12. The method of claim 11 , wherein the C max of dextromethorphan on the eighth day is at least about 10 ng/mL.
13. The method of claim 11 , wherein the C max of dextromethorphan on the eighth day is at least about 60 ng/mL.
14. The method of claim 11 , wherein the C max of dextromethorphan on the eighth day is at least about 80 ng/mL.
15. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in a C avg of dextromethorphan, over the period between two separate and consecutive administrations of dextromethorphan, that is at least about 5 ng/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC 0-12 of dextromethorphan is at least about 20 times the AUC 0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.
16. The method of claim 15 , wherein the erythrohydroxybupropion is administered in an amount that results in a C avg of dextromethorphan, over the period between two separate and consecutive administrations of dextromethorphan, that is at least about 60 ng/mL.
17. The method of claim 15 , wherein the C avg of dextromethorphan on the eighth day is at least about 8 ng/mL,
wherein the C avg is for the period between two separate and consecutive administrations of dextromethorphan, or
if dextromethorphan is administered only once on the eighth day, the C avg is for 12 hours after the only dose of dextromethorphan on the eighth day.
18. The method of claim 15 , wherein the C avg of dextromethorphan on the eighth day is at least about 30 ng/mL,
wherein the C avg is for the period between two separate and consecutive administrations of dextromethorphan, or
if dextromethorphan is administered only once on the eighth day, the C avg is for 12 hours after the only dose of dextromethorphan on the eighth day.